Condition
Solid Pseudopapillary Neoplasm of the Pancreas
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04851119Phase 1Recruiting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT07183280RecruitingPrimary
Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas
NCT06753318Not ApplicableNot Yet Recruiting
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions
NCT04728750CompletedPrimary
Laparoscopic Enucleation of Frantz's Tumor of the Pancreas
Showing all 4 trials